SAN DIEGO, March 07, 2023 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company's Cloudbreak® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023. "The preclinical data presented at ESMO TAT represent important progress for Cidara in oncology, as…
wpengineMarch 7, 2023